AcquisitionOther
Novartis AG acquired Tourmaline Bio, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Novartis AG -> Tourmaline Bio, Inc. · $1.4 billion
To acquire pacibekitug, an anti-IL-6 monoclonal antibody for cardiovascular disease treatment.
Open source record (SEC) ↗